Equities research analysts forecast that Edwards Lifesciences Co. (NYSE:EW) will announce $0.53 earnings per share for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for Edwards Lifesciences’ earnings. The lowest EPS estimate is $0.51 and the highest is $0.56. Edwards Lifesciences reported earnings of $0.51 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.9%. The company is expected to report its next quarterly earnings report on Wednesday, October 20th.
According to Zacks, analysts expect that Edwards Lifesciences will report full year earnings of $2.26 per share for the current financial year, with EPS estimates ranging from $2.23 to $2.30. For the next year, analysts expect that the firm will report earnings of $2.57 per share, with EPS estimates ranging from $2.32 to $2.70. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Edwards Lifesciences.
Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 29th. The medical research company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.09. The company had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.29 billion. Edwards Lifesciences had a return on equity of 29.73% and a net margin of 29.69%.
In related news, VP Huimin Wang sold 6,350 shares of the business’s stock in a transaction that occurred on Wednesday, September 8th. The stock was sold at an average price of $121.25, for a total value of $769,937.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,050 shares of the company’s stock in a transaction on Friday, September 10th. The stock was sold at an average price of $122.25, for a total value of $1,350,862.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 96,530 shares of company stock worth $11,055,715. Insiders own 1.35% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Baldrige Asset Management LLC purchased a new stake in Edwards Lifesciences during the second quarter worth $31,000. Bedel Financial Consulting Inc. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $31,000. Wagner Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter valued at $35,000. Concord Wealth Partners lifted its holdings in shares of Edwards Lifesciences by 106.5% during the 1st quarter. Concord Wealth Partners now owns 446 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 230 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $41,000. Institutional investors own 80.13% of the company’s stock.
NYSE EW opened at $118.50 on Wednesday. The company has a market capitalization of $73.86 billion, a PE ratio of 50.86, a price-to-earnings-growth ratio of 3.40 and a beta of 1.08. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.89 and a current ratio of 3.75. The business’s fifty day moving average is $115.06 and its 200 day moving average is $100.68. Edwards Lifesciences has a fifty-two week low of $70.92 and a fifty-two week high of $123.27.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.
Featured Article: How is a management fee different from a performance fee?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.